Basal cell carcinoma - Basale Sel Carcinoma
☆ AI Dermatology — Free Service
Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Ulcerated lesions dy't ynfloed hawwe op de hûd fan de noas by in âlder yndividu wurde faak diagnostisearre as Basale Sel Carcinoma (Basal cell carcinoma). De noas is in mienskiplik foarkommende lokaasje foar dit soarte hûdkanker.
Basale Sel Carcinoma (Basal cell carcinoma) kin foarkomme troch ûnregelmjittige rânen en zweren.
Basale Sel Carcinoma (Basal cell carcinoma) kin ferskine wurde mei wrat.
relevance score : -100.0%
ReferencesBasal cell carcinoma (BCC) is de meast foarkommende type hûdkanker. Blootstelling oan sinneljocht is de wichtichste oarsaak. Hast alle BCC‑gefallen litte oeraktive Hedgehog‑sinjalearring sjen yn 'e molekulêre analyse. Ferskate behannelingen binne beskikber en wurde keazen op basis fan weromfallrisiko, belang fan weefselbehâld, pasjintfoarkar en omfang fan de sykte.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas binne it meast foarkommende type hûdkanker by folwoeksenen mei ljochte hûd fan 50 jier en âlder. Harren oantal nimt wrâldwiid ta, benammen troch bleatstelling oan sinneljocht. Bepaalde genetyske omstannichheden kinne minsken gefoelich meitsje foar it ûntwikkeljen fan dizze kankers op in jongere leeftyd. Basal cell carcinomas fariearje yn earnst, fariearjend fan maklik te behanneljen oerflakkige of nodulêre lesions oant wiidweidiger dy't diskusje nedich is yn spesjalisearre medyske teams. De prognoaze hinget ôf fan de kâns dat de kanker weromkomt of fan har fermogen om tichtby weefsel te beskeadigjen. Surgery is de standertbehanneling foar de measte gefallen, garandearret krekte ferwidering en lit de kâns op weromkomst leech. Minder invasive metoaden kinne oerflakkige lesions effektyf behannelje.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
De primêre behanneling foar BCC is sjirurgy. Foar hege risiko of weromkommende BCC, benammen yn krityske gebieten, wurdt mikrografysk kontroleare sjirurgy oanrikkemandearre. Pasjinten mei leech‑risiko oerflakkige BCC kinne topike behannelingen as destruktive metoaden beskôgje. Fotodynamyske terapy wurket goed foar oerflakkige en lege‑risiko nodulêre BCC's. Foar lokaal avansearre of metastatyske BCC wurde Hedgehog‑ynhibitoren (vismodegib, sonidegib) oanrikkemandearre. As der sykte‑progression of yntolerânsje is foar Hedgehog‑ynhibitoren, kin immunotherapy mei anti‑PD1 antibody (cemiplimab) wurde beskôge. Radiotherapy is in goede opsje foar pasjinten dy't gjin sjirurgy kinne hawwe, benammen âldere pasjinten. Elektrochemotherapy kin beskôge wurde as sjirurgy of radiotherapy gjin opsje is.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Risikofaktoaren omfetsje bleatstelling oan ultraviolet ljocht, bestralingsterapy, langduorjende bleatstelling oan arseen en minne immúnsysteemfunksje (bgl. orgaantransplantaasje). Bleatstelling oan UV-ljocht yn 'e jeugd is benammen skealik.
Nei diagnoaze troch biopsie is behanneling typysk sjirurgyske ferwidering. Dit kin wêze troch ienfâldige eksisy as de kanker lyts is; as de kanker net lyts is, wurdt Mohs‑sjirurgy algemien oanrikkemandearre.
Basale selkanker makket teminsten 32 % fan alle kankers wrâldwiid út. Fan oare hûdkankers as melanoma binne sa’n 80 % basale selkankers. Yn 'e Feriene Steaten wurde sa’n 35 % fan de blanke mannen en 25 % fan de blanke froulju op in stuit yn harren libben beynfloede troch basale selkanker.
○ Diagnose en behanneling
#Dermoscopy
#Skin biopsy
#Mohs surgery